Drug profile · INN
amphotericin b
FUNGILIN
amphotericin b (FUNGILIN) is a ergosterol sequestering agent. Associated with Lacuna Pharma Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
Drug details — amphotericin b
- US status
- approved
- Class
- —
- Route
- TOPICAL
- Patents
- 8
- Programs
- 10
- Data quality
- 0.89
Quick answer
amphotericin b (FUNGILIN) is a ergosterol sequestering agent. Associated with Lacuna Pharma Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
Key facts
Mechanism of action
Ergosterol sequestering agent
Primary target: Ergosterol
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| TGA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Related patents
-
US 12409227
Cochleates made with soy phosphatidylserine
granted -
US 11964019
Cochleates made with soy phosphatidylserine
granted -
US 11389407
Cochleates and methods of using the same to enhance tissue penetration of pharmacologically active agent
granted -
US 10716860
Cochleates made with soy phosphatidylserine
granted -
US 10058521
Omega-3 pentaenoic acid compositions and methods of use
granted -
US 9775907
Cochleates made with soy phosphatidylserine
granted -
US 8906964
Methods of administering compositions comprising docosapentaenoic acid
granted -
US 7326691
Compositions comprising amphotericin B, methods, and systems
granted
Frequently asked questions
What is amphotericin b?
amphotericin b (FUNGILIN) is a ergosterol sequestering agent. Associated with Lacuna Pharma Pty Ltd. Route of administration: topical. Current US regulatory status: approved.
What is the brand name for amphotericin b?
FUNGILIN is a marketed brand name for amphotericin b. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of amphotericin b?
amphotericin b has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.